NEA Management Company, LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 14, 2025), NEA Management Company, LLC reported 37 stock positions worth $1.3 billion. Its top holding was Arcellx (ACLX) at 18.9% of the portfolio, followed by Verona Pharma (VRNA, 13.1%) and Rhythm Pharmaceuticals (RYTM, 11.9%). Compared with Q4 2024, it sold out of 4, added to 2 and reduced 3. The biggest buy was Senti Biosciences (SNTI, shares +753%) and the biggest sale an exit from Nextnav (NN).
- Most Recent 13F
- Q2 2026
- Location
- TIMONIUM, MD
- CIK
- 0001512848
- Portfolio Value
- $1.3B (Q1 2025)
- SEC Filing
- 0000897069-25-000979 ↗ filed May 14, 2025
Holdings Value
Holdings 37 stocks · $1.3B
| ACLX Arcellx Inc. | 18.92% | 3,745,262 | $245.7M | No change |
| VRNA Verona Pharma Ltd. | 13.15% | 2,688,565 | $170.7M | Reduce -51.9% |
| RYTM Rhythm Pharmaceuticals Inc. | 11.87% | 2,909,956 | $154.1M | No change |
| TEM Tempus AI Inc. Class A | 9.72% | 2,615,979 | $126.2M | Reduce -51.4% |
| COUR Coursera Inc. | 6.60% | 12,867,769 | $85.7M | No change |
| TRVI Trevi Therapeutics Inc. | 5.51% | 11,370,376 | $71.5M | No change |
| SVRA Savara Inc. | 5.22% | 24,471,264 | $67.8M | No change |
| CRSP Crispr Therapeutics AG | 4.16% | 1,587,854 | $54.0M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 2.75% | 7,692,298 | $35.7M | No change |
| AUPH Aurinia Pharmaceuticals Inc. | 2.46% | 3,969,834 | $31.9M | No change |
| MBX MBX Biosciences Inc. | 2.05% | 3,614,486 | $26.7M | No change |
| CVRX CVRX Inc. | 1.91% | 2,026,083 | $24.8M | No change |
| ZBIO Zenas Biopharma Inc. | 1.59% | 2,613,948 | $20.7M | No change |
| GOSS Gossamer Bio Inc. | 1.53% | 18,093,034 | $19.9M | No change |
| KRRO Korro Bio Inc. | 1.46% | 1,090,793 | $19.0M | No change |
| NEUE Neuehealth Inc. | 1.42% | 2,726,917 | $18.4M | No change |
| CSBR Champions Oncology Inc. | 1.15% | 1,713,720 | $14.9M | No change |
| SNTI Senti Biosciences Inc. | 0.98% | 3,775,615 | $12.7M | Add +753.0% |
| CELC Celcuity Inc. | 0.97% | 1,250,001 | $12.6M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 0.95% | 1,960,169 | $12.3M | No change |
| ORIC Oric Pharmaceuticals Inc. | 0.94% | 2,195,545 | $12.3M | Add +40.2% |
| RGLS Regulus Therapeutics Inc. | 0.87% | 6,467,802 | $11.3M | No change |
| DM Desktop Metal Inc. Class A | 0.54% | 1,439,892 | $7.1M | No change |
| BDTX Black Diamond Therapeutics I | 0.53% | 4,448,757 | $6.9M | No change |
| NKTX Nkarta Inc. | 0.51% | 3,568,781 | $6.6M | No change |
| BZFD Buzzfeed Inc. | 0.41% | 2,512,103 | $5.4M | Reduce -34.5% |
| IVA Inventiva SA - ADR | 0.33% | 1,462,586 | $4.3M | No change |
| SYBX Synlogic Inc. | 0.28% | 2,922,772 | $3.6M | No change |
| XFOR X4 Pharmaceuticals Inc. | 0.27% | 14,986,793 | $3.5M | No change |
| ADAPY Adaptimmune Therapeutics-ADR | 0.26% | 17,079,778 | $3.4M | No change |
| INZY Inozyme Pharma Inc. | 0.17% | 2,437,689 | $2.2M | No change |
| OKUR Onkure Therapeutics Inc. Class A | 0.16% | 478,548 | $2.1M | No change |
| MRKR Marker Therapeutics Inc. | 0.15% | 1,625,678 | $2.0M | No change |
| ALLK Allakos LLC | 0.11% | 6,147,260 | $1.4M | No change |
| IKENA ONCOLOGY INC | 0.06% | 600,063 | $768K | No change |
| AFMDQ Affimed NV | 0.02% | 442,648 | $320K | No change |
| UP Wheels Up Experience Inc. | 0.01% | 106,125 | $107K | No change |
Portfolio Sells Q4 2024 → Q1 2025
| NN Nextnav Inc. | Sold out | 0.00% | −7.19 |
| VRNA Verona Pharma Ltd. | Reduce -51.9% | 13.15% | −1.49 |
| GERN Geron Corp. | Sold out | 0.00% | −0.55 |
| TEM Tempus AI Inc. Class A | Reduce -51.4% | 9.72% | −0.54 |
| SGMT Sagimet Biosciences Inc. Class A | Sold out | 0.00% | −0.51 |
| BZFD Buzzfeed Inc. | Reduce -34.5% | 0.41% | −0.17 |
| LXRX Lexicon Pharmaceuticals Inc. | Sold out | 0.00% | −0.10 |
Portfolio Buys Q4 2024 → Q1 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 26 | $1.6B | TRVI, MBX, GLUE, CELC, SGP |
| Q1 2026 | 26 | $1.8B | ACLX, CELC, SGP, TRVI, SVRA |
| Q4 2025 | 27 | $2.0B | CELC, RYTM, ACLX, TRVI, SVRA |
| Q3 2025 | 29 | $1.8B | RYTM, ACLX, VRNA, COUR, TRVI |
| Q2 2025 | 32 | $1.3B | ACLX, VRNA, RYTM, COUR, CRSP |
| Q1 2025 | 37 | $1.3B | ACLX, VRNA, RYTM, TEM, COUR |
| Q4 2024 | 41 | $1.8B | ACLX, VRNA, TEM, RYTM, NN |
| Q3 2024 | 42 | $1.8B | ACLX, TEM, VRNA, RYTM, SVRA |
| Q2 2024 | 41 | $1.3B | ACLX, TEM, RYTM, SVRA, COUR |
| Q1 2024 | 44 | $1.6B | ACLX, CRSP, RYTM, SVRA, COUR |